Brokers' Take

AsiaPharm Group, June 14 closing : 49 cents

15 June 2004
The Business Times

DBS Vickers Research, June 14

The group is poised for strong growth over the next two years as it leverages on its strong R&D capabilities and established distribution network to gain a bigger share of the pharmaceutical drugs industry in China. Its flagship product commands a 77 per cent market share, while a pipeline of new products will drive prospective growth. With high barriers to entry in an industry heavily regulated by the government, and its R&D capabilities ensuring a steady stream of new products, the stock offers an attractive exposure to a growing industry. We are initiating coverage with a BUY recommendation.

Compiled by KENNETH LIM